Howard W. Bruckner

Oncology

2330 Eastchester Rd
Bronx, NY 10469

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Journal: Cancer

Published: June 29, 2026

Analysis of Clinical Benefit Using DNG64-CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing Cancers.

Analysis of Clinical Benefit Using DNG64-CAR-V Chimeric Tumor Targeted Amphotropic RNA Vector in CCNG1 Expressing Cancers.

Journal: Anticancer research

Published: January 20, 2026

Enhancing Toxicity Reporting With Objective Measures and Contemporary Tools.

Enhancing Toxicity Reporting With Objective Measures and Contemporary Tools.

Journal: JCO oncology practice

Published: May 30, 2025

Cholangiocarcinoma, sequential chemotherapy, and prognostic tests.

Cholangiocarcinoma, sequential chemotherapy, and prognostic tests.

Journal: Frontiers in oncology

Published: December 26, 2023

Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.

Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast.

Journal: Frontiers in molecular medicine

Published: November 22, 2022

Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times.

Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival times.

Journal: PloS one

Published: June 03, 2022

Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review.

Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review.

Journal: Molecular and clinical oncology

Published: December 03, 2020

Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn's Disease: A 9-Year Survival.

Ileal Adenocarcinoma with Liver Metastasis in Patient with Crohn's Disease: A 9-Year Survival.

Journal: Case reports in oncological medicine

Published: February 01, 2019

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.

A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer.

Journal: Molecular therapy oncolytics

Published: November 11, 2018

Cancer of the Pancreas-Actual 5, 10, and 20+Year Survival: The Lucky and Fortunate Few.

Cancer of the Pancreas-Actual 5, 10, and 20+Year Survival: The Lucky and Fortunate Few.

Journal: The Surgical clinics of North America

Published: December 02, 2017

Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.

Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.

Journal: Anticancer research

Published: August 03, 2017

Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores.

Targeted Therapy for Resistant Cholangiocarcinoma with Bevacizumab or Cetuximab Added to Failed Cytotoxic Drug Cores.

Journal: Anticancer research

Published: January 02, 2016

Showing 1-12 of 13

Last Updated: 09/26/2026